Vanderbilt University Medical Center: High-Dose Flu Vaccine Beneficial For Pediatric Stem Cell Transplant Patients
March 03, 2023
March 03, 2023
NASHVILLE, Tennessee, March 3 (TNSjou) -- Vanderbilt University Medical Center issued the following news:
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population.
The study was published in the New England Journal of Medicine, and the authors found that two dose . . .
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population.
The study was published in the New England Journal of Medicine, and the authors found that two dose . . .